
## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6221352/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. Journal of Hepatology, 2014, 60, 1268-1289.	3.7	1,151
2	Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment. Journal of Clinical Oncology, 2011, 29, 3140-3145.	1.6	615
3	Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2014, 149, 565.	4.3	585
4	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics, 2013, 45, 1470-1473.	21.4	564
5	Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplantation, 2005, 11, 1086-1092.	2.4	555
6	Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery, 2007, 141, 610-618.	1.9	408
7	Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis. Annals of Surgical Oncology, 2010, 17, 3129-3136.	1.5	400
8	Expanding Criteria for Resectability of Colorectal Liver Metastases. Oncologist, 2008, 13, 51-64.	3.7	389
9	Intrahepatic Cholangiocarcinoma: expert consensus statement. Hpb, 2015, 17, 669-680.	0.3	372
10	Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. Hpb, 2011, 13, 439-446.	0.3	345
11	Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis. Annals of Surgical Oncology, 2008, 15, 165-174.	1.5	331
12	A Proposed Staging System for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2009, 16, 14-22.	1.5	294
13	A Nomogram to Predict Long-term Survival After Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2014, 149, 432.	4.3	285
14	Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 Patients. Annals of Surgical Oncology, 2003, 10, 1059-1069.	1.5	284
15	The Tumor Burden Score. Annals of Surgery, 2018, 267, 132-141.	4.2	264
16	Epidemiology of Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2015, 24, 1-17.	1.5	256
17	Incidence of Finding Residual Disease for Incidental Gallbladder Carcinoma: Implications for Re-resection. Journal of Gastrointestinal Surgery, 2007, 11, 1478-1487.	1.7	242
18	Predictors of Survival After Resection of Early Hepatocellular Carcinoma. Annals of Surgery, 2009, 249, 799-805.	4.2	239

#	Article	IF	CITATIONS
19	Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery, 2013, 153, 811-818.	1.9	239
20	Risk of Morbidity and Mortality Following Hepato-Pancreato-Biliary Surgery. Journal of Gastrointestinal Surgery, 2012, 16, 1727-1735.	1.7	227
21	ls Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database. Annals of Surgical Oncology, 2005, 12, 364-373.	1.5	226
22	Limitations of Claims and Registry Data in Surgical Oncology Research. Annals of Surgical Oncology, 2008, 15, 415-423.	1.5	209
23	Surgical Therapy for Colorectal Metastases to the Liver. Journal of Gastrointestinal Surgery, 2007, 11, 1057-1077.	1.7	206
24	Critical Appraisal of the Clinical and Pathologic Predictors of Survival After Resection of Large Hepatocellular Carcinoma. Archives of Surgery, 2005, 140, 450.	2.2	203
25	Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. Annals of Surgical Oncology, 2016, 23, 235-243.	1.5	195
26	Liver metastases. Nature Reviews Disease Primers, 2021, 7, 27.	30.5	190
27	The Volume-Outcomes Effect in Hepato-Pancreato-Biliary Surgery: Hospital Versus Surgeon Contributions and Specificity of the Relationship. Journal of the American College of Surgeons, 2009, 208, 528-538.	0.5	186
28	Sarcopenia Adversely Impacts Postoperative Complications Following Resection or Transplantation in Patients with Primary Liver Tumors. Journal of Gastrointestinal Surgery, 2015, 19, 272-281.	1.7	185
29	The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 2873-2881.	1.5	184
30	Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. Hpb, 2010, 12, 289-299.	0.3	163
31	Early <i>versus</i> late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. British Journal of Surgery, 2018, 105, 848-856.	0.3	158
32	Textbook Outcomes Among Medicare Patients Undergoing Hepatopancreatic Surgery. Annals of Surgery, 2020, 271, 1116-1123.	4.2	158
33	Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?. Cancer, 2007, 110, 2484-2492.	4.1	153
34	Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. Annals of Surgical Oncology, 2011, 18, 3657-3665.	1.5	151
35	Association of <i>BRAF</i> Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surgery, 2018, 153, e180996.	4.3	151
36	A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2019, 154, e190571.	4.3	149

#	Article	IF	CITATIONS
37	Association of shared decision-making on patient-reported health outcomes and healthcare utilization. American Journal of Surgery, 2018, 216, 7-12.	1.8	140
38	Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis. Journal of the American College of Surgeons, 2014, 219, 664-675.	0.5	139
39	Liver Resection for Colorectal Metastases in Presence of Extrahepatic Disease: Results from an International Multi-institutional Analysis. Annals of Surgical Oncology, 2011, 18, 1380-1388.	1.5	138
40	Influence of Patient, Physician, and Hospital Factors on 30-Day Readmission Following Pancreatoduodenectomy in the United States. JAMA Surgery, 2013, 148, 1095.	4.3	137
41	Transplantation Versus Resection for Hilar Cholangiocarcinoma. Annals of Surgery, 2018, 267, 797-805.	4.2	137
42	Intra-arterial Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis. Annals of Surgical Oncology, 2013, 20, 3779-3786.	1.5	134
43	Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease. Annals of Surgical Oncology, 2006, 13, 712-720.	1.5	133
44	Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer, 2012, 118, 2674-2681.	4.1	132
45	Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Surgical Oncology, 2018, 27, 280-288.	1.6	132
46	Can hepatic resection provide a longâ€ŧerm cure for patients with intrahepatic cholangiocarcinoma?. Cancer, 2015, 121, 3998-4006.	4.1	131
47	Impact of complications on long-term survival after resection of colorectal liver metastases. British Journal of Surgery, 2013, 100, 711-718.	0.3	129
48	Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. Journal of Gastrointestinal Surgery, 2015, 19, 1581-1592.	1.7	129
49	Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2016, 23, 2610-2617.	1.5	128
50	The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 4020-4028.	1.5	126
51	Liver transplantation in patients with liver metastases from neuroendocrine tumors: AÂsystematic review. Surgery, 2017, 162, 525-536.	1.9	126
52	Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival. World Journal of Surgery, 2019, 43, 1777-1787.	1.6	126
53	Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets. Annals of Surgical Oncology, 2014, 21, 3827-3834.	1.5	123
54	A Systematic Review: Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma. Journal of the American College of Surgeons, 2012, 215, 820-830.	0.5	120

#	Article	IF	CITATIONS
55	Conditional Survival after Surgical Resection of Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 949 Patients. Journal of the American College of Surgeons, 2010, 210, 755-764.	0.5	119
56	Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis. Journal of the American College of Surgeons, 2012, 214, 769-777.	0.5	119
57	Personalized treatment of patients with very early hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 412-423.	3.7	119
58	Implementation Costs of an Enhanced Recovery After Surgery Program in the United States: A Financial Model and Sensitivity Analysis Based on Experiences at a Quaternary Academic Medical Center. Journal of the American College of Surgeons, 2016, 222, 219-225.	0.5	118
59	Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification. Annals of Surgical Oncology, 2019, 26, 3693-3700.	1.5	117
60	Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2020, 155, 823.	4.3	116
61	Association of Safety Culture with Surgical Site Infection Outcomes. Journal of the American College of Surgeons, 2016, 222, 122-128.	0.5	115
62	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Medicine, 2016, 13, e1002006.	8.4	113
63	Parenchymal-Sparing Versus Anatomic Liver Resection for Colorectal Liver Metastases: a Systematic Review. Journal of Gastrointestinal Surgery, 2017, 21, 1076-1085.	1.7	112
64	Association Between Specific Mutations in <i>KRAS</i> Codon 12 and Colorectal Liver Metastasis. JAMA Surgery, 2015, 150, 722.	4.3	108
65	Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 3704-3721.	3.3	107
66	Patient Readmission and Mortality after Surgery for Hepato-Pancreato-Biliary Malignancies. Journal of the American College of Surgeons, 2012, 215, 607-615.	0.5	106
67	Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases. British Journal of Surgery, 2018, 105, 1210-1220.	0.3	105
68	Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Annals of Surgery, 2021, 274, e1187-e1195.	4.2	105
69	Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis. Surgery, 2012, 152, 218-226.	1.9	103
70	County-level Social Vulnerability is Associated With Worse Surgical Outcomes Especially Among Minority Patients. Annals of Surgery, 2021, 274, 881-891.	4.2	103
71	Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surgical Oncology, 2017, 26, 125-137.	1.6	99
72	Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases. Annals of Surgery, 2017, 266, 641-649.	4.2	97

#	Article	IF	CITATIONS
73	Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2018, 44, 927-938.	1.0	97
74	Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study. Radiation Oncology, 2011, 6, 126.	2.7	95
75	High Social Vulnerability and "Textbook Outcomes―after Cancer Operation. Journal of the American College of Surgeons, 2021, 232, 351-359.	0.5	95
76	Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: A population-based analysis. Journal of Surgical Oncology, 2014, 110, 163-170.	1.7	94
77	Defining Post Hepatectomy Liver Insufficiency: Where do We stand?. Journal of Gastrointestinal Surgery, 2015, 19, 2079-2092.	1.7	92
78	Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. Journal of Gastrointestinal Surgery, 2018, 22, 52-59.	1.7	92
79	Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2015, 150, 538.	4.3	91
80	Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. Journal of Gastrointestinal Surgery, 2014, 18, 2136-2148.	1.7	90
81	Regret in Surgical Decision Making: A Systematic Review of Patient and Physician Perspectives. World Journal of Surgery, 2017, 41, 1454-1465.	1.6	87
82	Feasibility of a Randomized Trial of Extended Lymphadenectomy for Pancreatic Cancer. Archives of Surgery, 2005, 140, 584.	2.2	86
83	Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 4158-4165.	1.5	86
84	Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2017, 115, 696-703.	1.7	85
85	Readmission After Surgery. Advances in Surgery, 2014, 48, 185-199.	1.3	84
86	Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 991-998.	4.2	83
87	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 3716-3723.	1.5	83
88	The relative effect of hospital and surgeon volume on failure to rescue among patients undergoing liver resection for cancer. Surgery, 2016, 159, 1004-1012.	1.9	83
89	Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. British Journal of Surgery, 2020, 107, 854-864.	0.3	83
90	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2020, 9, 1129.	2.4	83

#	Article	IF	CITATIONS
91	Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. JAMA Surgery, 2017, 152, e165059.	4.3	81
92	Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis. Journal of Surgical Oncology, 2017, 116, 643-650.	1.7	80
93	Histopathological and immunophenotypic features of ipilimumabâ€associated colitis compared to ulcerative colitis. Journal of Internal Medicine, 2018, 283, 568-577.	6.0	78
94	A Systematic Review of the Factors that Patients Use to Choose their Surgeon. World Journal of Surgery, 2016, 40, 45-55.	1.6	76
95	The association of neighborhood social vulnerability with surgical textbook outcomes among patients undergoing hepatopancreatic surgery. Surgery, 2020, 168, 868-875.	1.9	76
96	Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Annals of Surgical Oncology, 2020, 27, 2321-2331.	1.5	76
97	Variation in Lymph Node Assessment After Colon Cancer Resection: Patient, Surgeon, Pathologist, or Hospital?. Journal of Gastrointestinal Surgery, 2011, 15, 471-479.	1.7	74
98	Understanding Variation in 30-Day Surgical Readmission in the Era of Accountable Care. JAMA Surgery, 2015, 150, 1042.	4.3	74
99	Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. Hpb, 2017, 19, 901-909.	0.3	74
100	Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. British Journal of Surgery, 2018, 105, 857-866.	0.3	74
101	Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 2549-2557.	1.5	74
102	Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases. Annals of Surgery, 2019, 269, 1129-1137.	4.2	74
103	Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 221, 291-299.	0.5	73
104	The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis. Journal of Surgical Oncology, 2016, 114, 803-809.	1.7	73
105	Clinical and morphometric parameters of frailty for prediction of mortality following hepatopancreaticobiliary surgery in the elderly. British Journal of Surgery, 2016, 103, e83-e92.	0.3	70
106	Recurrence Patterns and Prognostic Factors in Patients with Hepatocellular Carcinoma in Noncirrhotic Liver: A Multi-Institutional Analysis. Annals of Surgical Oncology, 2014, 21, 147-154.	1.5	68
107	A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2017, 24, 1343-1350.	1.5	68
108	KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2017, 24, 264-271.	1.5	68

#	Article	IF	CITATIONS
109	Emerging Approaches in the Management of Patients with Neuroendocrine Liver Metastasis: Role of Liver-Directed and Systemic Therapies. Journal of the American College of Surgeons, 2013, 216, 123-134.	0.5	66
110	Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 872-878.	0.3	66
111	A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion. Surgery, 2019, 165, 721-730.	1.9	66
112	Patient outcomes and provider perceptions following implementation of a standardized perioperative care pathway for open liver resection. British Journal of Surgery, 2016, 103, 564-571.	0.3	65
113	Frailty as a Risk Predictor of Morbidity and Mortality Following Liver Surgery. Journal of Gastrointestinal Surgery, 2017, 21, 822-830.	1.7	65
114	Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. Journal of Gastrointestinal Surgery, 2017, 21, 1841-1850.	1.7	65
115	Surgery for colorectal liver metastases: The evolution of determining prognosis. World Journal of Gastrointestinal Oncology, 2013, 5, 207.	2.0	64
116	Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 2398-2408.	1.5	63
117	A Nomogram to Predict Overall Survival and Disease-Free Survival After Curative Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1828-1835.	1.5	62
118	Enhanced Recovery After Surgery Protocols for Open Hepatectomy—Physiology, Immunomodulation, and Implementation. Journal of Gastrointestinal Surgery, 2015, 19, 387-399.	1.7	62
119	Impact of complications on longâ€ŧerm survival after resection of intrahepatic cholangiocarcinoma. Cancer, 2015, 121, 2730-2739.	4.1	61
120	Intrahepatic Cholangiocarcinoma: Prognosis of Patients Who Did Not Undergo Lymphadenectomy. Journal of the American College of Surgeons, 2015, 221, 1031-1040e4.	0.5	61
121	Conditional Survival after Surgical Resection of Gastric Cancer: A Multi-Institutional Analysis of the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 557-564.	1.5	61
122	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. Journal of the American College of Surgeons, 2016, 222, 750-759e2.	0.5	61
123	Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases. Journal of Gastrointestinal Surgery, 2016, 20, 1821-1829.	1.7	61
124	Intrahepatic Cholangiocarcinoma Treated with Local-Regional Therapy: Quantitative Volumetric Apparent Diffusion Coefficient Maps for Assessment of Tumor Response. Radiology, 2012, 264, 285-294.	7.3	60
125	A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the nationwide inpatient sample. Surgery, 2014, 156, 538-547.	1.9	60
126	Surgical Therapy for Early Hepatocellular Carcinoma in the Modern Era. Annals of Surgery, 2013, 258, 1022-1027.	4.2	59

#	Article	IF	CITATIONS
127	Safety and oncologic outcomes of robotic liver resections: A systematic review. Journal of Surgical Oncology, 2018, 117, 1517-1530.	1.7	59
128	Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. Annals of Surgical Oncology, 2020, 27, 3318-3327.	1.5	59
129	Profiles in social vulnerability: The association of social determinants of health with postoperative surgical outcomes. Surgery, 2021, 170, 1777-1784.	1.9	59
130	Risk factors and prediction model for inpatient surgical site infection after major abdominal surgery. Journal of Surgical Research, 2017, 217, 153-159.	1.6	58
131	Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 116, 133-139.	1.7	57
132	Liver transplantation for unresectable colorectal liver metastases: A systematic review. Journal of Surgical Oncology, 2017, 116, 288-297.	1.7	56
133	Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. Journal of Surgical Oncology, 2020, 121, 936-944.	1.7	56
134	Impact of Hospital Teaching Status on Length of Stay and Mortality Among Patients Undergoing Complex Hepatopancreaticobiliary Surgery in the USA. Journal of Gastrointestinal Surgery, 2013, 17, 2114-2122.	1.7	55
135	Lymphadenectomy for Intrahepatic Cholangiocarcinoma: Has Nodal Evaluation Been Increasingly Adopted by Surgeons over Time?A National Database Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 668-675.	1.7	55
136	Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. Surgery, 2019, 166, 983-990.	1.9	54
137	Influence of hospital teaching status on the chance to achieve a textbook outcome after hepatopancreatic surgery for cancer among Medicare beneficiaries. Surgery, 2020, 168, 92-100.	1.9	54
138	Association of County-Level Social Vulnerability with Elective Versus Non-elective Colorectal Surgery. Journal of Gastrointestinal Surgery, 2021, 25, 786-794.	1.7	54
139	Racial Disparity in Surgical Mortality after Major Hepatectomy. Journal of the American College of Surgeons, 2008, 207, 312-319.	0.5	53
140	Early Versus Late Readmission After Surgery Among Patients With Employer-provided Health Insurance. Annals of Surgery, 2015, 262, 502-511.	4.2	53
141	Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer, 2016, 122, 2698-2707.	4.1	53
142	Prognostic impact of complications after resection of early stage hepatocellular carcinoma. Journal of Surgical Oncology, 2017, 115, 791-804.	1.7	53
143	Trends in the Mortality of Hepatocellular Carcinoma in the United States. Journal of Gastrointestinal Surgery, 2017, 21, 2033-2038.	1.7	53
144	Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2017, 6, 67-78.	1.5	53

#	Article	IF	CITATIONS
145	Neutrophilâ€lymphocyte and plateletâ€lymphocyte ratio in patients after resection for hepatoâ€pancreaticoâ€biliary malignancies. Journal of Surgical Oncology, 2015, 111, 868-874.	1.7	52
146	Conditional Disease-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors. JAMA Surgery, 2015, 150, 299.	4.3	52
147	Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. Annals of Surgery, 2020, 272, 574-581.	4.2	52
148	Provider versus patient factors impacting hospital length of stay after pancreaticoduodenectomy. Surgery, 2013, 154, 152-161.	1.9	51
149	Impact of Anatomical Versus Non-anatomical Liver Resection on Short- and Long-Term Outcomes for Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 1841-1850.	1.5	51
150	Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer, 2015, 121, 3564-3573.	4.1	50
151	The importance of surgical margins in primary malignancies of the liver. Journal of Surgical Oncology, 2016, 113, 296-303.	1.7	50
152	Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. Annals of Surgical Oncology, 2016, 23, 3736-3743.	1.5	50
153	Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2019, 26, 1657-1668.	1.5	50
154	Trends in the Geospatial Distribution of Inpatient Adult Surgical Services across the United States. Annals of Surgery, 2021, 273, 121-127.	4.2	49
155	Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2016, 113, 685-691.	1.7	48
156	The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2018, 25, 1140-1149.	1.5	48
157	Defining Early Recurrence of Hilar Cholangiocarcinoma After Curativeâ€intent Surgery: A Multiâ€institutional Study from the US Extrahepatic Biliary Malignancy Consortium. World Journal of Surgery, 2018, 42, 2919-2929.	1.6	48
158	Referral Patterns and Treatment Choices for Patients with Hepatocellular Carcinoma: A United States Population-Based Study. Journal of the American College of Surgeons, 2013, 217, 896-906.	0.5	47
159	Surgical Management of Intrahepatic Cholangiocarcinoma: Defining an Optimal Prognostic Lymph Node Stratification Schema. Annals of Surgical Oncology, 2015, 22, 2772-2778.	1.5	47
160	Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Periâ€Operative Outcomes. World Journal of Surgery, 2018, 42, 2551-2560.	1.6	47
161	Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors â‰≌ cm after curative resection: A multiâ€institutional study of 392 cases. Journal of Surgical Oncology, 2019, 120, 1071-1079.	1.7	47
162	The Association Between Patient Satisfaction and Patient-Reported Health Outcomes. Journal of Patient Experience, 2019, 6, 201-209.	0.9	47

#	Article	IF	CITATIONS
163	Choosing a Cancer Surgeon: Analyzing Factors in Patient Decision Making Using a Best–Worst Scaling Methodology. Annals of Surgical Oncology, 2014, 21, 3732-3738.	1.5	46
164	The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients—A multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 115, 312-318.	1.7	46
165	The prognostic utility of the "Tumor Burden Score―based on preoperative radiographic features of colorectal liver metastases. Journal of Surgical Oncology, 2017, 116, 515-523.	1.7	45
166	Challenges of surgical management of intrahepatic cholangiocarcinoma. Expert Review of Gastroenterology and Hepatology, 2018, 12, 671-681.	3.0	45
167	Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. British Journal of Surgery, 2019, 106, 1228-1236.	0.3	45
168	Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. Surgery, 2019, 166, 967-974.	1.9	45
169	Hospital variation in Textbook Outcomes following curative-intent resection of hepatocellular carcinoma: an international multi-institutional analysis. Hpb, 2020, 22, 1305-1313.	0.3	45
170	Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. Journal of the American College of Surgeons, 2020, 230, 363-370.	0.5	45
171	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2016, 23, 2998-3008.	1.5	44
172	Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. American Surgeon, 2017, 83, 679-686.	0.8	44
173	The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2888-2901.	1.5	44
174	The timing of complications impacts risk of readmission after hepatopancreatobiliary surgery. Surgery, 2014, 155, 945-953.	1.9	43
175	The impact of the aging population and incidence of cancer on future projections of general surgical workforce needs. Surgery, 2018, 163, 553-559.	1.9	43
176	Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation?. Annals of Surgical Oncology, 2019, 26, 2959-2968.	1.5	43
177	Performance of prognostic scores and staging systems in predicting longâ€ŧerm survival outcomes after surgery for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2017, 116, 1085-1095.	1.7	42
178	Association of Neighborhood Characteristics with Utilization of High-Volume Hospitals Among Patients Undergoing High-Risk Cancer Surgery. Annals of Surgical Oncology, 2021, 28, 617-631.	1.5	42
179	A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated withÂResection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients. Annals of Surgical Oncology, 2020, 27, 1110-1119.	1.5	41
180	Dedicated Cancer Centers are More Likely to Achieve a Textbook Outcome Following Hepatopancreatic Surgery. Annals of Surgical Oncology, 2020, 27, 1889-1897.	1.5	41

#	Article	IF	CITATIONS
181	Association of County-Level Vulnerability, Patient-Level Race/Ethnicity, and Receipt of Surgery for Early-Stage Hepatocellular Carcinoma. JAMA Surgery, 2021, 156, 197.	4.3	41
182	Readmission incidence and associated factors after a hepatic resection at a major hepato-pancreatico-biliary academic centre. Hpb, 2014, 16, 972-978.	0.3	40
183	Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 116, 298-306.	1.7	39
184	Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. Hpb, 2018, 20, 277-284.	0.3	39
185	Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis. Journal of Gastrointestinal Surgery, 2019, 23, 1044-1054.	1.7	39
186	Prognostic utility of albuminâ€bilirubin grade for short―and longâ€term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multiâ€institutional analysis of 706 patients. Journal of Surgical Oncology, 2019, 120, 206-213.	1.7	39
187	Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. Surgery, 2019, 165, 548-556.	1.9	39
188	Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. American Journal of Surgery, 2020, 219, 478-483.	1.8	39
189	Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?. Annals of Surgical Oncology, 2016, 23, 708-713.	1.5	38
190	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. Journal of Gastrointestinal Surgery, 2018, 22, 859-871.	1.7	38
191	The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. Surgery, 2018, 164, 411-418.	1.9	38
192	Trends in centralization of surgical care and compliance with National Cancer Center Network guidelines for resected cholangiocarcinoma. Hpb, 2019, 21, 981-989.	0.3	38
193	Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines. Annals of Surgical Oncology, 2020, 27, 866-874.	1.5	38
194	Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis. Journal of Gastrointestinal Surgery, 2021, 25, 125-133.	1.7	38
195	The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma. World Journal of Surgery, 2015, 39, 1474-1484.	1.6	37
196	Evaluating Trends in the Volume-Outcomes Relationship Following Liver Surgery: Does Regionalization Benefit All Patients the Same?. Journal of Gastrointestinal Surgery, 2017, 21, 463-471.	1.7	37
197	Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons, 2018, 226, 393-403.	0.5	37
198	Effect of Surgical Margin Width on Patterns of Recurrence among Patients Undergoing R0 Hepatectomy for T1 Hepatocellular Carcinoma: An International Multi-Institutional Analysis. Journal of Gastrointestinal Surgery, 2020, 24, 1552-1560.	1.7	37

#	Article	IF	CITATIONS
199	The Impact of Mental Illness on Postoperative Outcomes Among Medicare Beneficiaries. Annals of Surgery, 2020, 272, 419-425.	4.2	37
200	The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. Hpb, 2020, 22, 1667-1674.	0.3	37
201	Neutrophilâ€lymphocyte and plateletâ€lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2015, 112, 164-172.	1.7	36
202	Hospital Volume and the Costs Associated with Surgery for Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1411-1419.	1.7	36
203	Nomogram predicting the risk of recurrence after curativeâ€intent resection of primary nonâ€metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2018, 117, 868-878.	1.7	36
204	New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2019, Publish Ahead of Print, e28-e35.	4.2	36
205	Textbook oncologic outcome is associated with increased overall survival after esophagectomy. Surgery, 2020, 168, 953-961.	1.9	36
206	Surgical treatment of hepatocellular carcinoma: Similar long-term results despite geographic variations. Liver Transplantation, 2004, 10, S74-S80.	2.4	35
207	Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterology Research and Practice, 2015, 2015, 1-14.	1.5	35
208	Neuroendocrine liver metastasis: The chance to be cured after liver surgery. Journal of Surgical Oncology, 2017, 115, 687-695.	1.7	35
209	Factors associated with decisional regret among patients undergoing major thoracic and abdominal operations. Surgery, 2017, 161, 1058-1066.	1.9	35
210	Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2018, 7, 270-276.	1.5	35
211	Spirituality and Religion in the Care of Surgical Oncology Patients with Life-Threatening or Advanced Illnesses. Annals of Surgical Oncology, 2008, 15, 3048-3057.	1.5	34
212	Quality of life after treatment of neuroendocrine liver metastasis. Journal of Surgical Research, 2015, 198, 155-164.	1.6	34
213	Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2017, 6, 35-43.	1.5	34
214	A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. Journal of Gastrointestinal Surgery, 2016, 20, 1098-1105.	1.7	33
215	Financial toxicity risk among adult patients undergoing cancer surgery in the United States: An analysis of the National Inpatient Sample. Journal of Surgical Oncology, 2019, 120, 397-406.	1.7	33
216	Impact of microvascular invasion on clinical outcomes after curativeâ€intent resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2019, 119, 21-29.	1.7	33

#	Article	IF	CITATIONS
217	Comparing textbook outcomes among patients undergoing surgery for cancer at U. S. News & World Report ranked hospitals. Journal of Surgical Oncology, 2020, 121, 927-935.	1.7	33
218	Multivisceral Resection for Gastric Cancer: Results from the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 840-847.	1.5	32
219	Novel Machine Learning Approach to Identify Preoperative Risk Factors Associated With Super-Utilization of Medicare Expenditure Following Surgery. JAMA Surgery, 2019, 154, 1014.	4.3	32
220	The optimal number of lymph nodes to evaluate among patients undergoing surgery for gallbladder cancer: Correlating the number of nodes removed with survival in 6531 patients. Journal of Surgical Oncology, 2019, 119, 1099-1107.	1.7	31
221	Development and Validation of a Laboratory Risk Score (LabScore) to Predict Outcomes after Resection for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons, 2020, 230, 381-391e2.	0.5	31
222	Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A populationâ€based analysis. Journal of Surgical Oncology, 2019, 119, 278-287.	1.7	30
223	Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?. Annals of Surgical Oncology, 2021, 28, 1970-1978.	1.5	30
224	Impact of Race/Ethnicity and County-Level Vulnerability on Receipt of Surgery Among Older Medicare Beneficiaries With the Diagnosis of Early Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 6309-6316.	1.5	30
225	Is Textbook Oncologic Outcome a Valid Hospital-Quality Metric after High-Risk Surgical Oncology Procedures?. Annals of Surgical Oncology, 2021, 28, 8028-8045.	1.5	30
226	Financial Impact of Postoperative Complication Following Hepato-Pancreatico-Biliary Surgery for Cancer. Annals of Surgical Oncology, 2016, 23, 1064-1070.	1.5	29
227	Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A populationâ€based analysis. Cancer, 2019, 125, 3767-3775.	4.1	29
228	Characterizing and Assessing the Impact of Surgery on Healthcare Spending Among Medicare Enrolled Preoperative Super-utilizers. Annals of Surgery, 2019, 270, 554-563.	4.2	29
229	Surgical Management of Advanced Gastrointestinal Stromal Tumors: An International Multi-Institutional Analysis of 158 Patients. Journal of the American College of Surgeons, 2014, 219, 439-449.	0.5	28
230	Routine portâ€site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multiâ€institution analysis from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2017, 115, 805-811.	1.7	28
231	Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. Hpb, 2018, 20, 956-965.	0.3	28
232	Tumor Necrosis Impacts Prognosis of Patients Undergoing Curative-Intent Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 797-805.	1.5	28
233	Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. Surgery, 2018, 163, 1114-1120.	1.9	27
234	Accessing surgical care for pancreaticoduodenectomy: Patient variation in travel distance and choice to bypass hospitals to reach higher volume centers. Journal of Surgical Oncology, 2019, 120, 1318-1326.	1.7	27

#	Article	IF	CITATIONS
235	Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma?. Annals of Surgical Oncology, 2019, 26, 2242-2250.	1.5	27
236	Intersectionality in cancer care: A systematic review of current research and future directions. Psycho-Oncology, 2022, 31, 705-716.	2.3	27
237	A Nomogram to Predict Disease-Free Survival After Surgical Resection of GIST. Journal of Gastrointestinal Surgery, 2014, 18, 2123-2129.	1.7	26
238	An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A sevenâ€institution analysis of 837 patients from the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2015, 112, 195-202.	1.7	26
239	Outcomes of Gastric Cancer Resection in Octogenarians: A Multi-institutional Study of the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 4371-4379.	1.5	26
240	Stage-Specific Prognostic Effect of Race in Patients with Resectable Gastric Adenocarcinoma: An 8-Institution Study of the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2016, 222, 633-643.	0.5	26
241	A novel online prognostic tool to predict longâ€ŧerm survival after liver resection for intrahepatic cholangiocarcinoma: The "metroâ€ŧicket―paradigm. Journal of Surgical Oncology, 2019, 120, 223-230.	1.7	26
242	Procedureâ€Specific Volume and Nurseâ€toâ€Patient Ratio: Implications for Failure to Rescue Patients Following Liver Surgery. World Journal of Surgery, 2019, 43, 910-919.	1.6	26
243	Race/Ethnicity and County-Level Social Vulnerability Impact Hospice Utilization Among Patients Undergoing Cancer Surgery. Annals of Surgical Oncology, 2021, 28, 1918-1926.	1.5	26
244	Assessment of Cancer Center Variation in Textbook Oncologic Outcomes Following Colectomy for Adenocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 775-785.	1.7	26
245	Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma. Cancers, 2021, 13, 747.	3.7	26
246	Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 556-563.	4.9	26
247	Post-treatment surveillance of patients with colorectal cancer with surgically treated liver metastases. Surgery, 2013, 154, 256-265.	1.9	25
248	Impact of early postoperative platelet count on volumetric liver gain and perioperative outcomes after major liver resection. British Journal of Surgery, 2016, 103, 899-907.	0.3	25
249	A Singular Hope: How the Discussion Around Cancer Surgery Sometimes Fails. Annals of Surgical Oncology, 2017, 24, 31-37.	1.5	25
250	Index versus Non-index Readmission After Hepato-Pancreato-Biliary Surgery: Where Do Patients Go to Be Readmitted?. Journal of Gastrointestinal Surgery, 2019, 23, 702-711.	1.7	25
251	Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 552-560.	1.5	25
252	Pre-hepatectomy carcinoembryonic antigen (CEA) levels among patients undergoing resection of colorectal liver metastases: do CEA levels still have prognostic implications?. Hpb, 2016, 18, 1000-1009.	0.3	24

#	Article	IF	CITATIONS
253	Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. Journal of the American College of Surgeons, 2016, 223, 794-803.	0.5	24
254	Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment. Journal of Gastrointestinal Surgery, 2017, 21, 1821-1830.	1.7	24
255	Association Between Travel Distance, Hospital Volume, and Outcomes Following Resection of Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2019, 23, 944-952.	1.7	24
256	Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium. Journal of Surgical Oncology, 2020, 121, 503-510.	1.7	24
257	Intersection of social vulnerability and residential diversity: Postoperative outcomes following resection of lung and colon cancer. Journal of Surgical Oncology, 2021, 124, 886-893.	1.7	24
258	Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. Journal of Clinical Medicine, 2021, 10, 104.	2.4	24
259	Influence of Nonclinical Factors on Choice of Therapy for Early Hepatocellular Carcinoma. Annals of Surgical Oncology, 2013, 20, 448-456.	1.5	23
260	Trends and Patterns of Utilization in Post-treatment Surveillance Imaging Among Patients Treated for Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 1774-1783.	1.7	23
261	Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: AÂMarkov decision model. Surgery, 2015, 158, 339-348.	1.9	23
262	Associations Between Patient Perceptions of Communication, Cure, and Other Patient-Related Factors Regarding Patient-Reported Quality of Care Following Surgical Resection of Lung and Colorectal Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 812-826.	1.7	23
263	Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 1225-1233.	1.5	23
264	A validated, risk assessment tool for predicting readmission after open ventral hernia repair. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2016, 20, 119-129.	2.0	23
265	Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. Journal of Gastrointestinal Surgery, 2017, 21, 2039-2047.	1.7	23
266	Impact of skilled nursing facility quality on postoperative outcomes after pancreatic surgery. Surgery, 2019, 166, 1-7.	1.9	23
267	Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2020, 121, 1201-1208.	1.7	23
268	Racial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2021, 25, 155-161.	1.7	23
269	Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. Annals of Surgical Oncology, 2022, 29, 4291-4303.	1.5	23
270	Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. Annals of Surgical Oncology, 2016, 23, 4401-4409.	1.5	22

#	Article	IF	CITATIONS
271	Outcomes After Resection of Hepatocellular Carcinoma: Intersection of Travel Distance and Hospital Volume. Journal of Gastrointestinal Surgery, 2019, 23, 1425-1434.	1.7	22
272	Understanding the Type of Support Offered Within the Caregiver, Family, and Spiritual/Religious Contexts of Cancer Patients. Journal of Pain and Symptom Management, 2019, 58, 56-64.	1.2	22
273	Variation in the cost-of-rescue among medicare patients with complications following hepatopancreatic surgery. Hpb, 2019, 21, 310-318.	0.3	22
274	Optimal Location for Centralization of Hospitals Performing Pancreas Resection in California. JAMA Surgery, 2020, 155, 261.	4.3	22
275	Trends and outcomes of simultaneous versus staged resection of synchronous colorectal cancer and colorectal liver metastases. Surgery, 2021, 170, 160-166.	1.9	22
276	Time-related changes in the prognostic significance of the total number of examined lymph nodes in node-negative pancreatic head cancer. Journal of Surgical Oncology, 2014, 110, 858-863.	1.7	21
277	Personalized treatment in patients with colorectal liver metastases. Journal of Surgical Research, 2017, 216, 26-29.	1.6	21
278	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. Annals of Surgical Oncology, 2020, 27, 1203-1212.	1.5	21
279	Examining healthcare inequities relative to United States safety net hospitals. American Journal of Surgery, 2020, 220, 525-531.	1.8	21
280	Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer. Annals of Surgical Oncology, 2021, 28, 417-425.	1.5	21
281	Association of social vulnerability with the use of high-volume and Magnet recognition hospitals for hepatopancreatic cancer surgery. Surgery, 2021, 170, 571-578.	1.9	21
282	Rural Surgery and Status of the Rural Workplace. Surgical Clinics of North America, 2020, 100, 835-847.	1.5	21
283	The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Consortium. Journal of Gastrointestinal Surgery, 2017, 21, 2016-2024.	1.7	20
284	Impact of Post-Discharge Disposition on Risk and Causes of Readmission Following Liver and Pancreas Surgery. Journal of Gastrointestinal Surgery, 2018, 22, 1221-1229.	1.7	20
285	Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined. Journal of Surgical Oncology, 2019, 120, 1302-1310.	1.7	20
286	Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. Hpb, 2020, 22, 215-223.	0.3	20
287	Patient Perceptions About the Role of Religion and Spirituality During Cancer Care. Journal of Religion and Health, 2020, 59, 1933-1945.	1.7	20
288	Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. Annals of Surgical Oncology, 2020, 27, 783-792.	1.5	20

#	Article	IF	CITATIONS
289	A Novel Machine-Learning Approach to Predict Recurrence After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2020, 27, 5139-5147.	1.5	20
290	A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis. Annals of Surgical Oncology, 2020, 27, 5224-5232.	1.5	20
291	Recurrence beyond the Milan criteria after curativeâ€intent resection of hepatocellular carcinoma: A novel tumorâ€burden based prediction model. Journal of Surgical Oncology, 2020, 122, 955-963.	1.7	20
292	Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 1156-1163.	1.7	20
293	Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma. European Journal of Surgical Oncology, 2021, 47, 660-666.	1.0	20
294	Marginalized patient identities and the patient-physician relationship in the cancer care context: a systematic scoping review. Supportive Care in Cancer, 2021, 29, 7195-7207.	2.2	20
295	Impact of Tumor Burden Score on Conditional Survival after Curativeâ€Intent Resection for Hepatocellular Carcinoma: A Multiâ€Institutional Analysis. World Journal of Surgery, 2021, 45, 3438-3448.	1.6	20
296	Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. World Journal of Surgery, 2017, 41, 224-231.	1.6	19
297	Hospice utilization among Medicare beneficiaries dying from pancreatic cancer. Journal of Surgical Oncology, 2019, 120, 624-631.	1.7	19
298	Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2019, 26, 1814-1823.	1.5	19
299	In-hospital Mortality Following Pancreatoduodenectomy: a Comprehensive Analysis. Journal of Gastrointestinal Surgery, 2020, 24, 1119-1126.	1.7	19
300	Surgical management of pancreatic neuroendocrine liver metastases. Journal of Gastrointestinal Oncology, 2020, 11, 590-600.	1.4	19
301	Quality of Care Among Medicare Patients Undergoing Pancreatic Surgery: Safety Grade, Magnet Recognition, and Leapfrog Minimum Volume Standards—Which Quality Benchmark Matters?. Journal of Gastrointestinal Surgery, 2021, 25, 269-277.	1.7	19
302	Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 4205-4213.	1.5	19
303	Validation of a Nomogram to Predict the Risk of Perioperative Blood Transfusion for Liver Resection. World Journal of Surgery, 2016, 40, 2481-2489.	1.6	18
304	Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab. British Journal of Surgery, 2017, 104, 926-935.	0.3	18
305	Updates and Critical Insights on Glissonian Approach in Liver Surgery. Journal of Gastrointestinal Surgery, 2018, 22, 154-163.	1.7	18
306	The Impact of Dedicated Cancer Centers on Outcomes Among Medicare Beneficiaries Undergoing Liver and Pancreatic Cancer Surgery. Annals of Surgical Oncology, 2019, 26, 4083-4090.	1.5	18

#	Article	IF	CITATIONS
307	Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multiâ€institutional analysis. Journal of Surgical Oncology, 2019, 120, 1080-1086.	1.7	18
308	Geographic Distribution of Adult Inpatient Surgery Capability in the USA. Journal of Gastrointestinal Surgery, 2019, 23, 1652-1660.	1.7	18
309	Routine intensive care unit admission among patients undergoing major pancreatic surgery for cancer: No effect on failure to rescue. Surgery, 2019, 165, 741-746.	1.9	18
310	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. Hpb, 2021, 23, 413-421.	0.3	18
311	The State of Immunotherapy in Hepatobiliary Cancers. Cells, 2021, 10, 2096.	4.1	18
312	Trends in Textbook Outcomes over Time: Are Optimal Outcomes Following Complex Gastrointestinal Surgery for Cancer Increasing?. Journal of Gastrointestinal Surgery, 2022, 26, 50-59.	1.7	18
313	Does the Volume-Outcome Association in Pancreas Cancer Surgery Justify Regionalization of Care? A Review of Current Controversies. Annals of Surgical Oncology, 2022, 29, 1257-1268.	1.5	18
314	Response to the Comment on "Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis― Annals of Surgery, 2021, 274, e743.	4.2	18
315	Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies. Cancers, 2021, 13, 5169.	3.7	18
316	Gastric remnant cancer: A distinct entity or simply another proximal gastric cancer?. Journal of Surgical Oncology, 2015, 112, 877-882.	1.7	17
317	Outcomes of Surgical and Endoscopic Resection of Duodenal Neuroendocrine Tumours (NETs): a Systematic Review of the Literature. Journal of Gastrointestinal Surgery, 2018, 22, 1652-1658.	1.7	17
318	Nomogram to predict perioperative blood transfusion for hepatopancreaticobiliary and colorectal surgery. British Journal of Surgery, 2016, 103, 1173-1183.	0.3	16
319	Cohort Contributions to Race―and Genderâ€Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA. World Journal of Surgery, 2018, 42, 835-840.	1.6	16
320	The Landmark Series: Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2859-2865.	1.5	16
321	Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Hpb, 2021, 23, 25-36.	0.3	16
322	Disparities in NCCNÂGuidelineÂCompliant Care for Resectable Cholangiocarcinoma at Minority-Serving Versus Non-Minority-Serving Hospitals. Annals of Surgical Oncology, 2021, 28, 8162-8171.	1.5	16
323	Postoperative Infectious Complications Worsen Long-Term Survival After Curative-Intent Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 315-324.	1.5	16
324	Surgical management of intrahepatic cholangiocarcinoma. Expert Review of Anticancer Therapy, 2022, 22, 27-38.	2.4	16

#	Article	IF	CITATIONS
325	The impact of extrahepatic disease among patients undergoing liverâ€directed therapy for neuroendocrine liver metastasis. Journal of Surgical Oncology, 2017, 116, 841-847.	1.7	15
326	Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Research, 2019, 234, 103-109.	1.6	15
327	Clinical relevance of performing endoscopic ultrasoundâ€guided fineâ€needle biopsy for pancreatic neuroendocrine tumors less than 2 cm. Journal of Surgical Oncology, 2020, 122, 1393-1400.	1.7	15
328	Assessment of utilization efficiency using machine learning techniques: A study of heterogeneity in preoperative healthcare utilization among super-utilizers. American Journal of Surgery, 2020, 220, 714-720.	1.8	15
329	A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surgical Oncology, 2021, 37, 101492.	1.6	15
330	The role of religion and spirituality in cancer care: An umbrella review of the literature. Surgical Oncology, 2022, 42, 101389.	1.6	15
331	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers, 2022, 14, 2018.	3.7	15
332	The Impact of Discharge Timing on Readmission Following Hepatopancreatobiliary Surgery: a Nationwide Readmission Database Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 1538-1548.	1.7	14
333	Understanding the use of attachment theory applied to the patient-provider relationship in cancer care: Recommendations for future research and clinical practice. Surgical Oncology, 2019, 31, 101-110.	1.6	14
334	Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases. Hpb, 2019, 21, 1230-1239.	0.3	14
335	Trends in the Geospatial Distribution of Adult Inpatient Surgical Cancer Care Across the United States. Journal of Gastrointestinal Surgery, 2020, 24, 2127-2134.	1.7	14
336	Travel to a high volume hospital to undergo resection of gallbladder cancer: does it impact quality of care and long-term outcomes?. Hpb, 2020, 22, 41-49.	0.3	14
337	Quality Versus Costs Related to Gastrointestinal Surgery: Disentangling the Value Proposition. Journal of Gastrointestinal Surgery, 2020, 24, 2874-2883.	1.7	14
338	Technical modifications and outcomes after Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) for primary liver malignancies: A systematic review. Surgical Oncology, 2020, 33, 70-80.	1.6	14
339	Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status. Journal of the American College of Surgeons, 2021, 232, 590-598.	0.5	14
340	Serum α-Fetoprotein Levels at Time of Recurrence Predict Post-Recurrence Outcomes Following Resection of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 7673-7683.	1.5	14
341	Association of County-Level Racial Diversity and Likelihood of a Textbook Outcome Following Pancreas Surgery. Annals of Surgical Oncology, 2021, 28, 8076-8084.	1.5	14
342	Association of Preoperative Body Mass Index with Surgical Textbook Outcomes Following Hepatectomy for Hepatocellular Carcinoma: A Multicenter Study of 1206 Patients. Annals of Surgical Oncology, 2022, 29, 4278-4286.	1.5	14

#	Article	IF	CITATIONS
343	A crossâ€sectional study of patient and provider perception of "cure―as a goal of cancer surgery. Journal of Surgical Oncology, 2016, 114, 677-683.	1.7	13
344	Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC. Journal of Gastrointestinal Surgery, 2018, 22, 1576-1584.	1.7	13
345	Minimally Invasive Versus Open Primary Resection for Retroperitoneal Soft Tissue Sarcoma: A Propensity-Matched Study From the National Cancer Database. Annals of Surgical Oncology, 2018, 25, 2209-2217.	1.5	13
346	Characterizing Perceptions Around the Patient-Oncologist Relationship: a Qualitative Focus Group Analysis. Journal of Cancer Education, 2020, 35, 447-453.	1.3	13
347	Interaction of Surgeon Volume and Nurse-to-Patient Ratio on Post-operative Outcomes of Medicare Beneficiaries Following Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2020, 24, 2551-2559.	1.7	13
348	Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Review of Anticancer Therapy, 2020, 20, 765-773.	2.4	13
349	Role of Node Dissection in Pancreatic Tumor Resection. Annals of Surgical Oncology, 2021, 28, 2374-2381.	1.5	13
350	A mixed-methods approach to understanding the role of religion and spirituality in healthcare provider well-being Psychology of Religion and Spirituality, 2020, 12, 487-493.	1.3	13
351	Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study. British Journal of Surgery, 2022, 109, 610-616.	0.3	13
352	Prognosis and Adherence with the National Comprehensive Cancer Network Guidelines of Patients with Biliary Tract Cancers: an Analysis of the National Cancer Database. Journal of Gastrointestinal Surgery, 2019, 23, 518-528.	1.7	12
353	U.S. News and World Report hospital ranking and surgical outcomes among patients undergoing surgery for cancer. Journal of Surgical Oncology, 2019, 120, 1327-1334.	1.7	12
354	Hot spotting surgical patients undergoing hepatopancreatic procedures. Hpb, 2019, 21, 765-772.	0.3	12
355	Patient preferences on the use of technology in cancer surveillance after curative surgery: A cross-sectional analysis. Surgery, 2019, 165, 782-788.	1.9	12
356	The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Review of Clinical Pharmacology, 2019, 12, 101-108.	3.1	12
357	Accessing surgical care for esophageal cancer: patient travel patterns to reach higher volume center. Ecological Management and Restoration, 2020, 33, .	0.4	12
358	Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. Neuroendocrinology, 2021, 111, 129-138.	2.5	12
359	State-of-the-art surgery for hepatocellular carcinoma. Langenbeck's Archives of Surgery, 2021, 406, 2151-2162.	1.9	12
360	Impact of hospital quality on surgical outcomes in patients with high social vulnerability: Association of textbook outcomes and social vulnerability by hospital quality. Surgery, 2022, 171, 1612-1618.	1.9	12

#	Article	IF	CITATIONS
361	Aspartate Î <sup>2</sup> -hydroxylase disrupts mitochondrial DNA stability and function in hepatocellular carcinoma. Oncogenesis, 2017, 6, e362-e362.	4.9	11
362	Outcomes of neoadjuvant chemotherapy before CRSâ€HIPEC for patients with appendiceal cancer. Journal of Surgical Oncology, 2020, 122, 388-398.	1.7	11
363	Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. Hepatobiliary Surgery and Nutrition, 2020, 9, 13-24.	1.5	11
364	Comparison of lymph node evaluation and yield among patients undergoing open and minimally invasive surgery for gallbladder adenocarcinoma. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 2223-2228.	2.4	11
365	Sexâ€based differences in time to surgical care among pancreatic cancer patients: A national study of Medicare beneficiaries. Journal of Surgical Oncology, 2021, 123, 236-244.	1.7	11
366	Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity scoreâ€natched analysis of the NCDB. Journal of Surgical Oncology, 2021, 123, 1558-1567.	1.7	11
367	Impact of Residential Racial Integration on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Resection for Cancer. Annals of Surgical Oncology, 2021, 28, 7566-7574.	1.5	11
368	Patient Social Vulnerability and Hospital Community Racial/Ethnic Integration: Do All Patients Undergoing Pancreatectomy Receive the Same Care Across Hospitals?. Annals of Surgery, 2021, 274, 508-515.	4.2	11
369	Patient Perspectives on Defining Textbook Outcomes Following Major Abdominal Surgery. Journal of Gastrointestinal Surgery, 2022, 26, 197-205.	1.7	11
370	Does minimally invasive pancreaticoduodenectomy increase the chance of a textbook oncologic outcome?. Surgery, 2021, 170, 880-888.	1.9	11
371	Textbook oncologic outcome in pancreaticoduodenectomy: Do regionalization efforts make sense?. Journal of Surgical Oncology, 2022, 125, 414-424.	1.7	11
372	Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping. Cancers, 2022, 14, 3284.	3.7	11
373	Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. Surgical Oncology, 2017, 26, 411-422.	1.6	10
374	Conditional diseaseâ€free survival after curativeâ€intent liver resection for neuroendocrine liver metastasis. Journal of Surgical Oncology, 2019, 120, 1087-1095.	1.7	10
375	Insurance Coverage Type Impacts Hospitalization Patterns Among Patients with Hepatopancreatic Malignancies. Journal of Gastrointestinal Surgery, 2020, 24, 1320-1329.	1.7	10
376	Assessing post-discharge costs of hepatopancreatic surgery: an evaluation of Medicare expenditure. Surgery, 2020, 167, 978-984.	1.9	10
377	The beliefs of cancer care providers regarding the role of religion and spirituality within the clinical encounter. Supportive Care in Cancer, 2021, 29, 909-915.	2.2	10
378	End-of-Life Hospice Use and Medicare Expenditures AmongÂPatients Dying of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 5414-5422.	1.5	10

#	Article	IF	CITATIONS
379	Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma. Hpb, 2021, 23, 1456-1466.	0.3	10
380	Association of Depression with In-Patient and Post-Discharge Disposition and Expenditures Among Medicare Beneficiaries Undergoing Resection for Cancer. Annals of Surgical Oncology, 2021, 28, 6525-6534.	1.5	10
381	Rural hospitals are not associated with worse postoperative outcomes for colon cancer surgery. Journal of Rural Health, 2022, 38, 650-659.	2.9	10
382	Variation in outcomes across surgeons meeting the Leapfrog volume standard for complex oncologic surgery. Cancer, 2021, 127, 4059-4071.	4.1	10
383	Assessment of Textbook Outcome After Surgery for Stage I/II Non-small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2022, 34, 1351-1359.	0.6	10
384	Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 2208.	3.7	10
385	Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis. Journal of Surgical Research, 2019, 241, 31-39.	1.6	9
386	New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy, 2020, 21, 183-191.	1.8	9
387	Variation in value among hospitals performing complex cancer operations. Surgery, 2020, 168, 106-112.	1.9	9
388	The impact of social vulnerability subthemes on postoperative outcomes differs by racial/ethnic minority status. American Journal of Surgery, 2022, 223, 353-359.	1.8	9
389	Survival Benefit of Primary Tumor Resection Among Elderly Patients with Pancreatic Neuroendocrine Tumors. World Journal of Surgery, 2021, 45, 3643-3651.	1.6	9
390	Social Vulnerability Subtheme Analysis Improves Perioperative Risk Stratification in Hepatopancreatic Surgery. Journal of Gastrointestinal Surgery, 2022, 26, 1171-1177.	1.7	9
391	Surgical treatment of gastric adenocarcinoma: Are we achieving textbook oncologic outcomes for our patients?. Journal of Surgical Oncology, 2022, 125, 621-630.	1.7	9
392	Adjuvant Therapy for Biliary Tract Cancers: New Evidence to Resolve Old Questions. Journal of Oncology Practice, 2018, 14, 723-724.	2.5	8
393	Early recurrence of wellâ€differentiated (G1) neuroendocrine liver metastasis after curativeâ€intent surgery: Risk factors and outcome. Journal of Surgical Oncology, 2018, 118, 1096-1104.	1.7	8
394	How Safe Are Safety-Net Hospitals? Opportunities to Improve Outcomes for Vulnerable Patients Undergoing Hepatopancreaticobiliary Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 2570-2578.	1.7	8
395	Intrapersonal Factors Impact Advance Care Planning Among Cancer Patients. American Journal of Hospice and Palliative Medicine, 2021, 38, 907-913.	1.4	8
396	Is Patient Satisfaction Dictated by Quality of Care Among Patients Undergoing Complex Surgical Procedures for a Malignant Indication?. Annals of Surgical Oncology, 2020, 27, 3126-3135.	1.5	8

#	Article	IF	CITATIONS
397	Impact of timeâ€ŧoâ€surgery on outcomes of patients undergoing curativeâ€intent liver resection for BCLCâ€0, A and B hepatocellular carcinoma. Journal of Surgical Oncology, 2021, 123, 381-388.	1.7	8
398	Optimal hepatic surgery: Are we making progress in North America?. Surgery, 2021, 170, 1741-1748.	1.9	8
399	Social vulnerability and fragmentation of postoperative surgical care among patients undergoing hepatopancreatic surgery. Surgery, 2022, 171, 1043-1050.	1.9	8
400	Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 1220-1229.	1.5	8
401	Is Hospital Occupancy Rate Associated With Postoperative Outcomes Among Patients Undergoing Hepatopancreatic Surgery?. Annals of Surgery, 2022, 276, 153-158.	4.2	8
402	Liver Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 227-241.	1.6	8
403	Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: Implication for Upfront Treatment Choice. Journal of Gastrointestinal Surgery, 2022, 26, 1021-1029.	1.7	8
404	Practices and Perceptions Among Surgical Oncologists in the Perioperative Care of Obese Cancer Patients. Annals of Surgical Oncology, 2018, 25, 2513-2519.	1.5	7
405	Understanding patient expectations around therapeutic benefits, risks, and the chance of cure. American Journal of Surgery, 2019, 217, 410-412.	1.8	7
406	Reciprocity within patient-physician and patient-spouse/caregiver dyads: insights into patient-centered care. Supportive Care in Cancer, 2019, 27, 1237-1244.	2.2	7
407	Photodynamic therapy may provide a benefit over systemic chemotherapy among nonâ€surgically managed patients with extrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2020, 121, 286-293.	1.7	7
408	Skilled nursing facility (SNF) utilization and impact of SNF star-quality ratings on outcomes following hepatectomy among Medicare beneficiaries. Hpb, 2020, 22, 109-115.	0.3	7
409	ASO Author Reflections: Centralization of High-Risk Cancer Surgery and Implications for Vulnerable Communities. Annals of Surgical Oncology, 2020, 27, 844-845.	1.5	7
410	Health expenditures and financial burden among patients with major gastrointestinal cancers relative to other common cancers in the United States. Surgery, 2020, 167, 985-990.	1.9	7
411	Does spiritual and religious orientation impact the clinical practice of healthcare providers?. Journal of Interprofessional Care, 2020, 34, 520-527.	1.7	7
412	Identification of patients who may benefit the most from adjuvant chemotherapy following resection of incidental gallbladder carcinoma. Journal of Surgical Oncology, 2021, 123, 978-985.	1.7	7
413	Assessment of Magnet status and Textbook Outcomes among medicare beneficiaries undergoing hepatoâ€pancreatic surgery for cancer. Journal of Surgical Oncology, 2021, 124, 334-342.	1.7	7
414	Association of Community Economic Distress and Breast and Colorectal Cancer Screening, Incidence, and Mortality Rates Among US Counties. Annals of Surgical Oncology, 2022, 29, 837-848.	1.5	7

#	ARTICLE	IF	CITATIONS
415	Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases. World Journal of Gastrointestinal Surgery, 2020, 12, 159-170.	1.5	7
416	Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, 29, 4326-4334.	1.5	7
417	Prognostic Utility of Systemic Immune-Inflammation Index After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2022, 29, 7605-7614.	1.5	7
418	Cancer surgeons' attitudes and practices about discussing the chance of operative "cure― Surgery, 2016, 160, 1619-1627.	1.9	6
419	The impact of a malignant diagnosis on the pattern and outcome of readmission after liver and pancreatic surgery: An analysis of the nationwide readmissions database. Journal of Surgical Oncology, 2018, 117, 1624-1637.	1.7	6
420	Discordance in prediction of prognosis among patients with intrahepatic cholangiocarcinoma: A preoperative vs postoperative perspective. Journal of Surgical Oncology, 2019, 120, 946-955.	1.7	6
421	Utilization of High-Volume Hospitals for High-Risk Cancer Surgery in California Following Medicaid Expansion. Journal of Gastrointestinal Surgery, 2021, 25, 1875-1884.	1.7	6
422	Current Advances in Minimally Invasive Surgical Management of Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 2143-2149.	1.7	6
423	Impact of Metabolic Syndrome on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Hepatectomy. Journal of Gastrointestinal Surgery, 2021, 25, 2545-2552.	1.7	6
424	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers, 2021, 13, 2242.	3.7	6
425	Financial Impact of Out-of-Pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma. Annals of Surgical Oncology, 2022, 29, 5387-5397.	1.5	6
426	Local referrals as a strategy for increasing value of surgical care among medicare patients undergoing liver and pancreatic surgery. Hpb, 2019, 21, 1552-1562.	0.3	5
427	Minimally Invasive Liver Resection for Early-Stage Hepatocellular Carcinoma: Inconsistent Outcomes from Matched or Weighted Cohorts. Journal of Gastrointestinal Surgery, 2020, 24, 560-568.	1.7	5
428	CMS Hospital Compare System of Star Ratings and Surgical Outcomes Among Patients Undergoing Surgery for Cancer: Do the Ratings Matter?. Annals of Surgical Oncology, 2020, 27, 3138-3146.	1.5	5
429	Redefining Conditional Overall and Disease-Free Survival After Curative Resection for Intrahepatic Cholangiocarcinoma: a Multi-institutional, International Study of 1221 patients. Journal of Gastrointestinal Surgery, 2020, 24, 2756-2765.	1.7	5
430	Provision of supportive spiritual care for hepatopancreatic cancer patients: an unmet need?. Hpb, 2021, 23, 1400-1409.	0.3	5
431	Prognostication in hepatocellular carcinoma: is it a burden or a ticket?. British Journal of Surgery, 2021, 108, 337-339.	0.3	5
432	The Influence of Patient and Provider Religious and Spiritual Beliefs on Treatment Decision Making in the Cancer Care Context. Medical Decision Making, 2022, 42, 125-134.	2.4	5

#	Article	IF	CITATIONS
433	Healthcare provider self-reported observations and behaviors regarding their role in the spiritual care of cancer patients. Supportive Care in Cancer, 2021, 29, 4405-4412.	2.2	5
434	Preoperative continuity of care and its relationship with cost of hepatopancreatic surgery. Surgery, 2020, 168, 809-815.	1.9	4
435	Assessing a Surgeon's Competency for High-Risk Procedures. JAMA Network Open, 2020, 3, e203888.	5.9	4
436	Assessment of hospital quality and safety standards among Medicare beneficiaries undergoing surgery for cancer. Surgery, 2021, 169, 573-579.	1.9	4
437	The religious/spiritual beliefs and needs of cancer survivors who underwent cancer-directed surgery. Palliative and Supportive Care, 2021, 19, 175-181.	1.0	4
438	Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: Pancreaticoduodenectomy. Annals of Surgical Oncology, 2021, 28, 6965-6969.	1.5	4
439	ASO Author Reflections: Development and Validation of Distal Cholangiocarcinoma Early Recurrence (DICER) Score: Results from the US Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2021, 28, 4214-4215.	1.5	4
440	Hepatopancreatic Surgery in the Rural United States: Variation in Outcomes at Critical Access Hospitals. Journal of Surgical Research, 2021, 261, 123-129.	1.6	4
441	Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 7624-7633.	1.5	4
442	Geographic Disparities in Oncologic Treatment and Outcomes: The Urban–Rural Divide. Annals of Surgical Oncology, 2021, 28, 8011-8013.	1.5	4
443	Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis. Annals of Surgical Oncology, 2020, 27, 3717-3726.	1.5	4
444	Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 5177-5185.	1.5	4
445	Surgical outcomes of gastroâ€enteroâ€pancreatic neuroendocrine tumors C3 versus neuroendocrine carcinoma. Journal of Surgical Oncology, 2022, 126, 689-697.	1.7	4
446	Short- and long-term outcomes following robotic and open resection for intrahepatic cholangiocarcinoma: A national cohort study. Surgical Oncology, 2022, 43, 101790.	1.6	4
447	ASO Author Reflections: Which Patients Benefit the Most From Lymphadenectomy During Resection for Intrahepatic Cholangiocarcinoma?. Annals of Surgical Oncology, 2019, 26, 2969-2970.	1.5	3
448	ASO Author Reflections: Routine Lymphadenectomy Should be Recommended Regardless of Morphologic Subtype of Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 2251-2252.	1.5	3
449	Exploring the perception of survivors on the bidirectional impact between cancer and their social contexts: A mixed-methods approach. Palliative and Supportive Care, 2019, 17, 668-676.	1.0	3
450	A systematic review of the methods utilised to measure the relationship between cancer patients and oncologists: Implications for future research and practice. European Journal of Cancer Care, 2019, 28, e12981.	1.5	3

#	Article	IF	CITATIONS
451	County-Level Variation in Utilization of Surgical Resection for Early-Stage Hepatopancreatic Cancer Among Medicare Beneficiaries in the USA. Journal of Gastrointestinal Surgery, 2021, 25, 1736-1744.	1.7	3
452	Characterizing Pastoral Care Utilization by Cancer Patients. American Journal of Hospice and Palliative Medicine, 2021, 38, 758-765.	1.4	3
453	Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough?. Journal of Surgical Oncology, 2021, 123, 1568-1577.	1.7	3
454	Letter to the Editor: Does Multiple Intrahepatic Cholangiocarcinoma Worsen Prognosis as "M1― Stage?. Hepatology, 2021, 74, 1128-1128.	7.3	3
455	Pancreatic neuroendocrine tumours: conservative versus surgical management. British Journal of Surgery, 2021, 108, 1267-1269.	0.3	3
456	Implications of intensive care unit admissions among medicare beneficiaries following resection of pancreatic cancer. Journal of Surgical Oncology, 2022, 125, 405-413.	1.7	3
457	Assessing the Impact of Provider Training and Perceived Barriers on the Provision of Spiritual Care: a Mixed Methods Study. Journal of Cancer Education, 2023, 38, 301-308.	1.3	3
458	Does Extended Lymphadenectomy Help in Pancreatic Cancer?. Annals of Surgical Oncology, 2022, 29, 2131.	1.5	3
459	Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Review of Anticancer Therapy, 2022, 22, 297-306.	2.4	3
460	Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis. Journal of Gastrointestinal Surgery, 2022, 26, 1697-1704.	1.7	3
461	ASO Author Reflections: Use of Machine Learning to Identify Patients with Intrahepatic Cholangiocarcinoma Who Could Benefit More from Neoadjuvant Therapies. Annals of Surgical Oncology, 2020, 27, 1120-1121.	1.5	2
462	Development and validation of a real-time mortality risk calculator before, during and after hepatectomy: an analysis of the ACS NSQIP database. Hpb, 2020, 22, 1158-1167.	0.3	2
463	ASO Author Reflections: Influence of Patient Clinical- and Treatment-Level Factors on Religious/Spiritual Preferences During Cancer Care. Annals of Surgical Oncology, 2020, 27, 753-754.	1.5	2
464	ASO Author Reflections: Patient Satisfaction and Quality of Care. Annals of Surgical Oncology, 2020, 27, 3136-3137.	1.5	2
465	Refusal of Surgery Among Patients with Early-Stage Hepato-Pancreato-Biliary Cancers: Predictive Factors and Outcomes. Journal of Gastrointestinal Surgery, 2021, 25, 1573-1575.	1.7	2
466	ASO Author Reflections: A Nomogram to Predict Recurrence after Curative-Intent Resection for Neuroendocrine Liver Metastasis. Annals of Surgical Oncology, 2020, 27, 3727-3728.	1.5	2
467	Assessing Differences in Cancer Surgeon Approaches to Patient-Centered Decision-Making Using Vignette-Based Methodology. Annals of Surgical Oncology, 2020, 27, 2149-2156.	1.5	2
468	ASO Author Reflections: Recurrence Patterns and Outcomes After Resection of Hepatocellular Carcinoma Within and Beyond the Barcelona Clinic Liver Cancer Criteria. Annals of Surgical Oncology, 2020, 27, 2332-2333.	1.5	2

#	Article	IF	CITATIONS
469	Do Religious/Spiritual Preferences and Needs of Cancer Patients Vary Based on Clinical- and Treatment-Level Factors?. Annals of Surgical Oncology, 2021, 28, 59-66.	1.5	2
470	The association of Hospital Medicare beneficiary payer-mix, national quality rankings and outcomes following hepatopancreatic surgery. American Journal of Surgery, 2021, 221, 492-496.	1.8	2
471	Insurance status and highâ€volume surgical cancer: Access to highâ€quality cancer care. Cancer, 2021, 127, 507-509.	4.1	2
472	Recurrence of Nonâ€functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burdenâ€Based Prediction Model. World Journal of Surgery, 2021, 45, 2134-2141.	1.6	2
473	ASO Author Reflections: Association of Depression with In-Patient and Post-Discharge Disposition and Expenditures Among Medicare Beneficiaries Undergoing Resection for Cancer. Annals of Surgical Oncology, 2021, 28, 6535-6536.	1.5	2
474	Trends in Discharge Disposition Following Hepatectomy for Hepatocellular Carcinoma Among Medicare Beneficiaries. Journal of Gastrointestinal Surgery, 2021, 25, 2842-2850.	1.7	2
475	ASO Visual Abstract: Association of Depression with In-Patient and Postdischarge Disposition and Expenditures Among Medicare Beneficiaries Undergoing Resection for Cancer. Annals of Surgical Oncology, 2021, 28, 429-429.	1.5	2
476	Timing and Severity of Postoperative Complications and Associated 30-Day Mortality Following Hepatic Resection: a National Surgical Quality Improvement Project Study. Journal of Gastrointestinal Surgery, 2022, 26, 314-322.	1.7	2
477	Geospatial Inefficiencies Associated With Digital Replantations at High-Volume Centers and Optimal Allocation Model for Centralization of Replantations. Journal of Hand Surgery, 2021, 46, 731-739.e5.	1.6	2
478	ASO Author Reflections: Association of Community Economic Distress and Breast and Colorectal Cancer Screening, Incidence, and Mortality Rates among U.S. Counties. Annals of Surgical Oncology, 2021, , 1.	1.5	2
479	Tumour Burden Score: An Authentic, Easy-To-Use Prognostic Marker for Hepatocellular Carcinoma. British Journal of Surgery, 2020, 107, e626.	0.3	2
480	ASO Author Reflections: Advances in the Multidisciplinary Management of Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2866-2867.	1.5	2
481	Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma. Hepatic Medicine: Evidence and Research, 2021, Volume 13, 93-104.	2.5	2
482	Nontumor related risk score: A new tool to improve prediction of prognosis after hepatectomy for colorectal liver metastases. Surgery, 2022, 171, 1580-1587.	1.9	2
483	Impact of neighborhood characteristics on textbook outcome following major surgery. American Journal of Surgery, 2022, 224, 959-964.	1.8	2
484	The Impact of Tumor Burden on Survival Differs by Morphological Subtype Among Patients Diagnosed with Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2022, 26, 1764-1765.	1.7	2
485	The impact of hospital volume and surgeon volume on perioperative outcomes of oncologic liver surgery. Journal of the American College of Surgeons, 2015, 221, e107.	0.5	1
486	ASO Author Reflections: Understanding Recurrence Patterns and Time Courses of Intrahepatic Cholangiocarcinoma After Surgery Helps in Postoperative Surveillance and Treatment. Annals of Surgical Oncology, 2019, 26, 2558-2559.	1.5	1

#	Article	IF	CITATIONS
487	ASO Author Reflections: Resection for Hepatocellular Carcinoma Beyond the BCLC Guidelines—How Can Machine Learning Techniques Help?. Annals of Surgical Oncology, 2020, 27, 875-876.	1.5	1
488	Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. Journal of Surgical Oncology, 2020, 122, 442-449.	1.7	1
489	ASO Author Reflections: Chance of Textbook Outcome following Hepatopancreatic Surgery Varies Based on Cancer Center Designation. Annals of Surgical Oncology, 2020, 27, 1898-1899.	1.5	1
490	ASO Author Reflections: Identification of Intrahepatic Cholangiocarcinoma Clusters Using Machine Learning Techniques: Should Patients be Treated Differently?. Annals of Surgical Oncology, 2020, 27, 5233-5234.	1.5	1
491	ASO Author Reflections: Minimally Invasive Surgery for Hepatocellular Carcinoma in the Setting of Portal Vein Hypertension. Annals of Surgical Oncology, 2020, 27, 3372-3373.	1.5	1
492	Comparing Surgeon Approaches to Patient-Centered Cancer Care Using Vignette Methodology. Journal of Gastrointestinal Surgery, 2021, 25, 1307-1315.	1.7	1
493	Inter-surgeon variability is associated with likelihood to undergo minimally invasive hepatectomy and postoperative mortality. Hpb, 2021, 23, 840-846.	0.3	1
494	ASO Author Reflections: Validated Prediction Model of Early Recurrence after Resection for Gallbladder Cancer: Identifying a Subset of Patients Who May be Better Served with Neoadjuvant Therapy. Annals of Surgical Oncology, 2021, 28, 428-429.	1.5	1
495	ASO Author Reflections: County-Level Social Vulnerability Associated with Disparities in Pancreatic Cancer Treatment, Especially among Patients from Racial and Ethnic Minorities. Annals of Surgical Oncology, 2021, 28, 6317-6318.	1.5	1
496	ASO Author Reflections: Multi-institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 7634-7635.	1.5	1
497	Surgeon Strategies to Patient-Centered Decision-making in Cancer Care: Validation and Applications of a Conceptual Model. Journal of Cancer Education, 2022, 37, 1719-1726.	1.3	1
498	Impact of Perioperative Thromboembolic Complications on Future Long-term Risk of Venous Thromboembolism among Medicare Beneficiaries Undergoing Complex Gastrointestinal Surgery. Journal of Gastrointestinal Surgery, 2021, 25, 3064-3073.	1.7	1
499	Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. Hepatobiliary Surgery and Nutrition, 2021, 10, 515-517.	1.5	1
500	ASO Author Reflections: Optimizing End-of-Life Care for Patients Dying from Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 5423-5424.	1.5	1
501	Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. , 2015, 121, 3564.		1
502	ASO Visual Abstract: Association of Community Economic Distress and Breast and Colorectal Cancer Screening, Incidence, and Mortality Rates Among U.S. Counties. Annals of Surgical Oncology, 2021, , 1.	1.5	1
503	A mixedâ€methods approach to comparing perceptions of cancer patients' and cancer care providers' religious and spiritual beliefs, behaviours, and attitudes. European Journal of Cancer Care, 2021, 30, e13390.	1.5	1
504	ASO Author Reflections: Impact of Tumor Necrosis on Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, 29, 2975-2976.	1.5	1

#	Article	IF	CITATIONS
505	Machine Learning Approach to Stratifying Prognosis Relative to Tumor Burden after Resection of Colorectal Liver Metastases: An International Cohort Analysis. Journal of the American College of Surgeons, 2022, 234, 504-513.	0.5	1
506	Using Machine Learning to Preoperatively Stratify Prognosis among Patients with Gallbladder Cancer: A Multi-Institutional Analysis. Hpb, 2022, , .	0.3	1
507	Surveillance for hepatocellular carcinoma with ultrasound and AFP is associated with improvements in tumour detection, receipt of curative therapy and overall survival in patients with cirrhosis. Evidence-Based Medicine, 2014, 19, 225-226.	0.6	0
508	Comment on: Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. British Journal of Surgery, 2019, 106, 1100-1101.	0.3	0
509	ASO Author Reflections: Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2019, 26, 610-611.	1.5	0
510	ASO Author Reflections: Trends in the Number of Lymph Nodes Evaluated Following Resection of Pancreatic Neuroendocrine Tumors—An Increasing Adoption of the AJCC Guidelines?. Annals of Surgical Oncology, 2020, 27, 1213-1214.	1.5	0
511	Response to comments on "Impact of tumor size and nodal status on the recurrence of nonfunctional pancreatic neuroendocrine tumors â‰≌ cm after curative resection: a multiâ€institutional study of 392 casesâ€i Journal of Surgical Oncology, 2020, 121, 411-412.	1.7	0
512	ASO Author Reflections: Development and Validation of a Novel Risk Score Using Machine-Learning Methodology to Predict Recurrence After Hepatectomy for Colorectal Liver Metastases. Annals of Surgical Oncology, 2020, 27, 5148-5149.	1.5	0
513	ASO Author Reflections: Assessing the Outcomes of Liver Cancer Patients Undergoing Surgery Over the Last Decade—Are We Doing Better?. Annals of Surgical Oncology, 2020, 27, 3328-3329.	1.5	0
514	ASO Author Reflections: The Influence of Surgeon Characteristics on Patient-Centered Approaches to Treatment Decision-Making. Annals of Surgical Oncology, 2020, 27, 2157-2158.	1.5	0
515	ASO Author Reflections: How Does Social Vulnerability Impact Hospice Utilization Among Patients Undergoing Cancer Surgery?. Annals of Surgical Oncology, 2021, 28, 1927-1928.	1.5	0
516	Moving Toward a More Informed Approach to Risk Stratification of Patients: Comments on Seror et al. CT-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related HCC. Annals of Surgical Oncology, 2021, 28, 24-26.	1.5	0
517	ASO Visual Abstract: Defining and Predicting Early Recurrence After Resection for Gallbladder Cancer. Annals of Surgical Oncology, 2021, 28, 426-427.	1.5	0
518	ASO Author Reflections: Tumor Burden in Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 1979-1980.	1.5	0
519	Conditional Recurrence-Free Survival for Patients with Gallbladder Cancer: A Personalized Resource for Patients and Providers. Annals of Surgical Oncology, 2021, 28, 2436-2437.	1.5	0
520	ASO Author Reflections: Impact of Residential Racial Integration on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Resection for Cancer. Annals of Surgical Oncology, 2021, 28, 7575-7576.	1.5	0
521	ASO Author Reflections: AFP Levels at the Time of Recurrence Predict Post-recurrence Outcomes Irrespective of Modality Used to Treat Recurrence. Annals of Surgical Oncology, 2021, 28, 7684-7685.	1.5	0
522	ASO Author Reflections: Minority-Serving Hospitals are Associated with Lower Likelihood of Providing NCCN Guideline Compliant Care to Patients with Resectable Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 8172-8173.	1.5	0

#	Article	IF	CITATIONS
523	ASO Author Reflections: County-Level Racial Diversity is Associated with Textbook Outcomes for Pancreatic Surgery. Annals of Surgical Oncology, 2021, 28, 8085-8086.	1.5	0
524	Editorial: Enhanced Recovery after Surgery Pathways: Improving the Perioperative Experience and Outcomes of Cancer Surgery Patients. Annals of Surgical Oncology, 2021, 28, 6929-6931.	1.5	0
525	ASO Author Reflections: Postoperative Infectious Complications Worsen Long-Term Survival After Curative-Intent Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, , 1.	1.5	0
526	ASO Author Reflections: Understanding the Broader Implications of the Volume–Outcome Impact on Pancreas Cancer Surgery. Annals of Surgical Oncology, 2021, , 1.	1.5	0
527	Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis. American Journal of Surgery, 2021, 222, 570-576.	1.8	0
528	Spiritual Motivations to Practice Medicine: A Survey of Cancer Care Providers. American Journal of Hospice and Palliative Medicine, 2021, , 104990912110498.	1.4	0
529	Stereotactic radiation treatment planning with volumetric modulated arc therapy: Impact of duodenal sparing on pancreatic tumor coverage Journal of Clinical Oncology, 2011, 29, 301-301.	1.6	0
530	Treatment of neuroendocrine liver metastases: a patent landscape review. Pharmaceutical Patent Analyst, 2020, 9, 29-32.	1.1	0
531	ASO Author Reflections: Hepatocellular Carcinoma-Related Tumor Necrosis is Associated with Worse Long-Term Outcomes. Annals of Surgical Oncology, 2021, 28, 806-807.	1.5	0
532	ASO Author Reflections: The Financial Impact of Out-of-Pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0
533	ASO Author Reflections: Association of County-level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment Among Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0
534	ASO Author Reflections: Is Systemic Immune-Inflammation Index a Useful Biomarker After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 0, , .	1.5	0
535	ASO Author Reflections: Dynamic Prediction of Survival After Curative Resection of Intrahepatic Cholangiocarcinoma: A Landmarking-Based Analysis. Annals of Surgical Oncology, 0, , .	1.5	0